Erlotinib protects against LPS-induced endotoxicity because TLR4 needs EGFR to signal.
about
Annexin A2 binds to endosomes and negatively regulates TLR4-triggered inflammatory responses via the TRAM-TRIF pathway.Cross talk between AT1 receptors and Toll-like receptor 4 in microglia contributes to angiotensin II-derived ROS production in the hypothalamic paraventricular nucleusT cells suppress memory-dependent rapid mucous cell metaplasia in mouse airways.Glioblastoma Cancer Stem Cells Evade Innate Immune Suppression of Self-Renewal through Reduced TLR4 Expression.EGFR Inhibition Blocks Palmitic Acid-induced inflammation in cardiomyocytes and Prevents Hyperlipidemia-induced Cardiac Injury in Mice.Selenium Deficiency Deteriorate the Inflammation of S. aureus Infection via Regulating NF-κB and PPAR-γ in Mammary Gland of Mice.Inhibition of epidermal growth factor receptor attenuates LPS-induced inflammation and acute lung injury in rats.Genetic or pharmacologic inhibition of EGFR ameliorates sepsis-induced AKI.Integration of Canonical and Noncanonical Pathways in TLR4 Signaling: Complex Regulation of the Wound Repair Program.Endogenous ligands of TLR4 promote unresolving tissue fibrosis: Implications for systemic sclerosis and its targeted therapy.The EGF epidermal growth factor counteracts Tat modulation of human endogenous retroviruses of the W family in astrocytes.Keratin 6a reorganization for ubiquitin-proteasomal processing is a direct antimicrobial response.IRF9 and unphosphorylated STAT2 cooperate with NF-κB to drive IL6 expression.Gram-negative bacteria facilitate tumor progression through TLR4/IL-33 pathway in patients with non-small-cell lung cancer.Targeting CREB-binding protein overrides LPS induced radioresistance in non-small cell lung cancer cell lines.Inhibition of Epidermal Growth Factor Receptor (EGFR) Reduces Lipopolysaccharide (LPS)-Induced Activation and Inflammatory Cytokines in Hepatic Stellate Cells In Vitro
P2860
Q36242151-7233D2EA-C9EA-4F3D-8078-4C035E86F740Q36699626-FF845433-61EE-4C1F-BAE0-14727A2A2D9DQ37356608-23564AFE-69E8-4FFB-9287-2057BC625879Q38721207-DB25528E-CB4F-4441-AC05-23EC50485323Q38777485-FF22DBD0-2DE9-4A88-AF5C-263BA2929C24Q40915588-33D86072-744D-4A6A-AF5B-D795577D0BDAQ41891577-B906DDEF-1B51-47D7-B71F-EE9FFB3E934AQ47137909-028CE98E-022C-4F4A-92B9-F1063A0C57FAQ47167999-45A52C57-BBD9-4045-97CC-ABE77FF3528EQ47753846-0E6DBD28-F0F4-4D71-A91D-635924CC6DDCQ48187859-97BCA1B9-C160-43B0-8503-0AF597B454EEQ48207699-54484553-B830-44B4-A34F-1FEE5B187E99Q51415880-2B5DAAEF-65E6-4E23-8644-D525501B832AQ52641579-9080CD22-BD4D-4B2A-B020-035974AA3077Q55508831-D360BAB8-60CE-43CB-AE16-EB7099302DF8Q58792997-15556AD8-DA2D-4180-9DC0-2A63E8B20A25
P2860
Erlotinib protects against LPS-induced endotoxicity because TLR4 needs EGFR to signal.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Erlotinib protects against LPS-induced endotoxicity because TLR4 needs EGFR to signal.
@ast
Erlotinib protects against LPS-induced endotoxicity because TLR4 needs EGFR to signal.
@en
type
label
Erlotinib protects against LPS-induced endotoxicity because TLR4 needs EGFR to signal.
@ast
Erlotinib protects against LPS-induced endotoxicity because TLR4 needs EGFR to signal.
@en
prefLabel
Erlotinib protects against LPS-induced endotoxicity because TLR4 needs EGFR to signal.
@ast
Erlotinib protects against LPS-induced endotoxicity because TLR4 needs EGFR to signal.
@en
P2093
P2860
P356
P1476
Erlotinib protects against LPS-induced endotoxicity because TLR4 needs EGFR to signal.
@en
P2093
Colleen M Croniger
David DeSantis
George R Stark
Sarmishtha De
Xiaoxia Li
P2860
P304
P356
10.1073/PNAS.1511794112
P407
P577
2015-07-20T00:00:00Z